AstraZeneca Faces Call For Sanctions
In their briefs filed Tuesday opposing AstraZeneca's motion to implement case-specific discovery and calling for sanctions, plaintiffs argue the pharmaceutical company's plan is “anything but efficient, cost effective or fair.”
The product liability action, in which plaintiffs allege a link between Seroquel and organ damage, has been mired in disputes over information disclosure for several months.
AstraZeneca had asked a Florida district...
To view the full article, register now.